PD L1 News and Research

RSS

AMSBIO's fully characterized and annotated FFPE tissue blocks can help streamline research projects

AMSBIO has established an unmatched commercial biorepository and procurement network that includes a large selection of fully characterized and annotated Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks to help streamline your research.

From AMS Biotechnology 1 Jul 2021

A new way to predict positive outcomes of immunotherapy in patients with bladder cancer

Researchers have detected and validated groups of genes linked to immunotherapy resistance in patients with metastatic urothelial cancer of the bladder.

12 Apr 2021

High expression of cell death genes linked to increased risk of dying early from lung cancer

Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.

6 Apr 2021

Immune cells in cerebrospinal fluid could be biomarkers to predict immunotherapy response

Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.

9 Mar 2021

New algorithm identifies 'escaping' cells in single-cell CRISPR screens

A team of researchers from New York has developed a new computational tool to help understand the function and regulation of human genes.

3 Mar 2021

New computational tool reveals the function and regulation of human genes

A new computational tool has been developed by a research team from New York to figure out the regulation and function of human genes.

2 Mar 2021

New technique reveals the tricks that cancer cells use to avoid immunotherapies

By harnessing the immune system against cancer, immunotherapies have revolutionized the way some types of cancer are treated. But most patients--across cancer types--do not respond, and in most cases, scientists are at a loss as to why.

2 Mar 2021

Fecal microbiota transplant helps cancer patients respond to immunotherapy

For patients with cancers that do not respond to immunotherapy drugs, adjusting the composition of microorganisms in the intestines--known as the gut microbiome--through the use of a stool, or fecal, transplants may help some of these individuals respond to the immunotherapy drugs, a new study suggests.

From National Cancer Institute (NCI) 5 Feb 2021

Proteogenomic study may lead to more effective treatments for head and neck squamous cell carcinoma

Proteogenomic studies may provide a better understanding of how to match cancer patients with an effective treatment for their specific cancer.

8 Jan 2021

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.

8 Dec 2020

Study unravels how immunotherapy is 'uniquely suppressed' by liver cancers

Though cancer immunotherapy has become a promising standard-of-care treatment--and in some cases, perhaps a cure--for a wide variety of different cancers, it doesn't work for everyone, and researchers have increasingly turned their attention to understanding why.

5 Oct 2020

New data shows immunotherapy is beneficial for patients with gastric, esophageal cancers

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival. (1-3)

24 Sep 2020

In-depth study of kidney tumors reveals novel markers of response to immunotherapy

Treatments for kidney cancer have improved considerably over the past few decades. In 1988, when Memorial Sloan Kettering oncologist Robert Motzer started researching the disease, the average survival was less than one year.

9 Sep 2020

Newly developed transplantable human cells can help cure type 1 diabetes

Researchers have made a significant advancement in the quest for a safe, effective treatment for type 1 diabetes.

20 Aug 2020

Removing copper from the blood can destroy some of the deadliest cancers

Australian researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.

20 Aug 2020

A genetic link discovered to predict treatment response for patients with rare, aggressive cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

Study shows engineered natural killer immune cells can directly kill tumor cells

According to a study, researchers have successfully designed natural killer immune cells that destroy head and neck tumor cells in mice.

8 Jul 2020

Manipulating immune cells could be a viable strategy for treating cancer

Most traditional cancer therapies target either the tumor cells themselves or indiscriminately kill any rapidly dividing cell.

From UC San Diego 23 Jun 2020

Combination therapy encourages innate immune cells to eat GBM tumors

A combination of immunotherapy agents that encourages some immune cells to eat cancer cells and alert others to attack tumors put mice with a deadly type of brain cancer called glioblastoma into long-term remission, a new study led by UT Southwestern scientists suggests.

24 Apr 2020